Brief: Vaccinex reports Q2 results
15/08/2022 14:25
Aug 15 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX REPORTS SECOND QUARTER 2022 RESULTS AND PROVIDES
CORPORATE UPDATE; EXCELLENT PROGRESS IN PEPINEMAB CLINICAL
PROGRAMS
* VACCINEX INC - QTRLY LOSS PER SHARE $0.13
* VACCINEX - INITIATED RANDOMIZED, DOUBLE-BLIND, PHASE 1/2A
SIGNAL-AD STUDY IN 40 SUBJECTS WITH EARLY AD, SEES STUDY TO
COMPLETE ENROLLMENT BY Q1 2023
Source text for Eikon: ID:nGNX25mFnY
Further company coverage: VCNX.O
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease